M. A. Seguí Palmer

Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study.

H. Wildiers, J. Jassem, L. Dirix, 2015, Breast.

Intensive chemotherapy in poor-prognosis nonseminomatous germ cell tumors of the testis.

H. Villavicencio, M. C. Climent Duran, M. A. Seguí Palmer, 1992, European urology.

SEOM clinical guidelines in advanced and recurrent breast cancer (2018)

Mafalda Oliveira, S. López-Tarruella Cobo, J. Gavilá Gregori, 2019, Clinical and Translational Oncology.

New clinical trials regulation in Spain: analysis of royal decree 1090/2015

R. García-Campelo, E. González-Flores, M. Martín Jiménez, 2016, Clinical and Translational Oncology.